Janux Therapeutics, Inc. (JANX): Shareholders' Equity
$956.82M
As of 2025-12-31
$927.98M
As of 2026-06-30
+44.0%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $956.82M | -6.4% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $1.02B | +197.0% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $344.35M | +7.4% | 2026-02-26, Balance as of period end |
| 2022-12-31 | $320.74M | -12.4% | 2025-02-27, Balance as of period end |
| 2021-12-31 | $366.33M | n/m | 2023-03-10, Balance as of period end |
| 2020-12-31 | -$14.64M | n/a | 2022-03-18, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $956.82M | -6.4% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $242.14M | -22.5% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $20.91M | -45.7% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $280.47M | -42.4% |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $203.01M | n/m |
| International Stem Cell Corp (ISCO) | 2025-12-31 | -$4.06M | n/m |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $272.05M | -15.8% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | -$18.69M | n/m |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $4.53B | -3.4% |
Compare JANX, ZBIO, PGEN, PRTA side by side · Screen every company in Pharmaceutical Preparations ↗